Phase III Randomised Trial to Evaluate the Benefit of Adjuvant Hormonal Treatment With Leuprorelin Acetate (Eligard, 45 mg) for 24 Months After Radical Prostatectomy in Patients With High Risk of Recurrence.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 May 2018
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 06 May 2018 Planned End Date changed from 1 Jan 2023 to 1 Sep 2027.
- 06 May 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Sep 2027.
- 06 May 2018 Status changed from recruiting to active, no longer recruiting.